Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2025
Immunology and Microbiology journal rankings 2025
130 ranked journals · Field in Life Sciences
Immunology and Microbiology has 130 ranked journals in 2025. The median journal has an OJR of 0.85, below the world average of 1.00, down 0.01 on 2024; Q1 starts at OJR 1.17. The highest-scoring journal with a stable rank is Immunity: its likely rank is within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Immunology and Microbiology (5)
Up to Life Sciences130 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #1 of 130ImmunityCell Press · United States | 5.75Q1 | 22.29 3.01 up from 2024 | 696 | 65% | $10,400 | ||
Rank 2; likely between #2 and #7 of 130Nature reviews. ImmunologyNature Portfolio · United Kingdom | 4.28Q1 | 22.91 0.47 up from 2024 | 427 | 11% | — | ||
Rank 3; likely between #2 and #7 of 130Cellular and Molecular ImmunologySpringer Nature · China | 4.09Q1 | 17.27 4.42 up from 2024 | 415 | 91% | $5,190 | Rising vs field, 2022–25 | |
Rank 4; likely between #2 and #7 of 130Nature ImmunologyNature Portfolio · United States | 3.96Q1 | 14.68 1.46 down from 2024 | 803 | 44% | $12,690 | ||
Rank 5; likely between #2 and #9 of 130Annual Review of ImmunologyAnnual Reviews · United States | 3.79Q1 | 39.29 5.05 up from 2024 | 74 | 97% | — | ||
Rank 6; likely between #3 and #8 of 130Science ImmunologyAmerican Association for the Advancement of Science · United States | 3.63Q1 | 14.06 0.51 down from 2024 | 493 | 45% | — | ||
Rank 7; likely between #2 and #11 of 130Clinical Reviews in Allergy & ImmunologySpringer Nature · United States | 3.44Q1 | 9.59 0.80 down from 2024 | 104 | 35% | $5,490 | ||
Rank 8; likely between #4 and #10 of 130Seminars in ImmunopathologySpringer Science+Business Media · Germany | 3.21Q1 | 11.53 2.08 up from 2024 | 114 | 76% | $3,790 | ||
Rank 9; likely between #8 and #12 of 130Journal of Allergy and Clinical ImmunologyElsevier BV · United States | 2.59Q1 | 8.10 0.08 down from 2024 | 1,054 | 54% | $4,900 | ||
Rank 10; likely between #8 and #13 of 130The Journal of Experimental MedicineRockefeller University Press · United States | 2.47Q1 | 9.20 0.25 down from 2024 | 600 | 85% | — | Falling vs field, 2022–25 | |
Rank 11; likely between #9 and #14 of 130Journal of AutoimmunityElsevier BV · United Kingdom | 2.43Q1 | 6.88 0.84 down from 2024 | 372 | 61% | $5,420 | ||
Rank 12; likely between #8 and #15 of 130Seminars in ImmunologyElsevier BV · United States | 2.41Q1 | 11.32 3.02 up from 2024 | 163 | 59% | $4,370 | ||
Rank 13; likely between #8 and #18 of 130BioDrugsAdis, Springer Healthcare · Switzerland | 2.23Q1 | 8.95 0.52 up from 2024 | 174 | 57% | $5,190 | Rising vs field, 2022–25 | |
Rank 14; likely between #9 and #18 of 130Immunity & AgeingOABioMed Central · United Kingdom | 2.10Q1 | 8.22 1.58 up from 2024 | 221 | 100% | $3,190 | ||
Rank 15; likely between #12 and #18 of 130Mucosal ImmunologyOAElsevier BV · United States | 1.99Q1 | 5.24 2.37 down from 2024 | 287 | 100% | $4,370 | ||
Rank 16; likely between #14 and #17 of 130Frontiers in ImmunologyOAFrontiers Media · Switzerland | 1.89Q1 | 7.16 0.63 up from 2024 | 18,991 | 100% | $3,801 | ||
Rank 17; likely between #14 and #24 of 130Inflammation ResearchSpringer Science+Business Media · Switzerland | 1.69Q1 | 6.11 0.49 up from 2024 | 415 | 24% | $4,790 | ||
Rank 18; likely between #12 and #45 of 130Current Research in ImmunologyElsevier BV · Netherlands | 1.64Q1 | 8.21 2.41 up from 2024 | 49 | — | $2,520 | ||
Rank 19; likely between #17 and #22 of 130Parasites & VectorsOABioMed Central · United Kingdom | 1.62Q1 | 3.88 0.05 down from 2024 | 1,465 | 100% | $3,090 | Rising vs field, 2022–25 | |
Rank 20; likely between #17 and #24 of 130Ticks and Tick-borne DiseasesOAElsevier BV · Germany | 1.59Q1 | 3.35 0.14 down from 2024 | 394 | 100% | $3,010 | Rising vs field, 2022–25 | |
Rank 21; likely between #16 and #29 of 130Current Research in Parasitology and Vector-Borne DiseasesOAElsevier BV · Netherlands | 1.53Q1 | 3.07 0.36 down from 2024 | 144 | 100% | $2,350 | ||
Rank 22; likely between #16 and #33 of 130Immune NetworkOASouth Korea | 1.49Q1 | 6.00 1.42 up from 2024 | 141 | 100% | — | ||
Rank 23; likely between #20 and #34 of 130ImmunologyWiley · United Kingdom | 1.37Q1 | 5.33 0.63 up from 2024 | 387 | 63% | $5,330 | ||
Rank 24; likely between #17 and #48 of 130International Reviews of ImmunologyTaylor & Francis · United States | 1.37Q1 | 5.74 2.45 up from 2024 | 58 | 6% | — | ||
Rank 25; likely between #20 and #39 of 130Cytokine & Growth Factor ReviewsElsevier BV · United Kingdom | 1.33Q1 | 13.74 2.67 up from 2024 | 156 | 35% | $4,900 | ||
Rank 26; likely between #22 and #43 of 130International Journal for ParasitologyElsevier BV · Australia | 1.26Q1 | 3.13 0.32 down from 2024 | 206 | 63% | $2,880 | ||
Rank 27; likely between #20 and #48 of 130Pathogens and DiseaseOxford University Press · United Kingdom | 1.25Q1 | 3.44 0.32 up from 2024 | 109 | 100% | $3,297 | Rising vs field, 2022–25 | |
Rank 28; likely between #21 and #47 of 130Food and Waterborne ParasitologyOAElsevier BV · United States | 1.25Q1 | 2.69 1.28 down from 2024 | 79 | 100% | $2,500 | ||
Rank 29; likely between #22 and #47 of 130Trends in ImmunologyElsevier BV · United Kingdom | 1.23Q1 | 7.22 0.62 down from 2024 | 403 | 50% | $7,030 | ||
Rank 30; likely between #19 and #68 of 130Drug Healthcare and Patient SafetyOADove Medical Press · New Zealand | 1.23Q1 | 4.35 0.07 up from 2024 | 50 | 100% | $2,320 | ||
Rank 31; likely between #24 and #45 of 130ParasiteOAEDP Sciences · France | 1.19Q1 | 2.86 0.26 up from 2024 | 203 | 100% | $1,695 | ||
Rank 32; likely between #27 and #42 of 130Clinical ImmunologyElsevier BV · Netherlands | 1.18Q1 | 3.99 0.01 up from 2024 | 684 | 40% | $4,400 | ||
Rank 33; likely between #25 and #45 of 130CytokineElsevier BV · United Kingdom | 1.17Q1 | 3.64 0.59 down from 2024 | 782 | 29% | $3,220 | ||
Rank 34; likely between #26 and #47 of 130Infection and ImmunityOAAmerican Society for Microbiology · United States | 1.15Q2 | 3.48 0.37 up from 2024 | 498 | 100% | — | Rising vs field, 2022–25 | |
Rank 35; likely between #24 and #52 of 130Parasite Epidemiology and ControlOAElsevier BV · United Kingdom | 1.15Q2 | 2.38 0.92 down from 2024 | 143 | 100% | $1,800 | ||
Rank 36; likely between #17 and #73 of 130Genes and ImmunitySpringer Nature · United States | 1.15Q2 | 3.15 0.56 down from 2024 | 144 | 46% | $3,190 | ||
Rank 37; likely between #18 and #74 of 130RetrovirologyOABioMed Central · United Kingdom | 1.13Q2 | 4.25 0.11 up from 2024 | 64 | 100% | $2,890 | ||
Rank 38; likely between #26 and #50 of 130Clinical & Translational ImmunologyOAWiley · Australia | 1.13Q2 | 3.47 0.58 down from 2024 | 185 | 100% | $3,070 | ||
Rank 39; likely between #28 and #50 of 130Expert Opinion on Biological TherapyTaylor & Francis · United Kingdom | 1.11Q2 | 3.59 0.27 down from 2024 | 323 | 39% | — | ||
Rank 40; likely between #28 and #49 of 130Zoonoses and Public HealthWiley · Germany | 1.11Q2 | 2.60 0.06 up from 2024 | 274 | 69% | $4,880 | Rising vs field, 2022–25 | |
Rank 41; likely between #25 and #54 of 130The AAPS JournalSpringer Science+Business Media · United States | 1.11Q2 | 3.50 0.52 down from 2024 | 315 | 54% | $5,090 | ||
Rank 42; likely between #29 and #49 of 130Clinical & Experimental ImmunologyOxford University Press · United Kingdom | 1.11Q2 | 3.59 0.27 down from 2024 | 373 | 99% | $3,816 | ||
Rank 43; likely between #22 and #77 of 130Psoriasis Targets and TherapyOADove Medical Press · New Zealand | 1.05Q2 | 3.23 3.91 down from 2024 | 51 | 100% | $2,320 | ||
Rank 44; likely between #29 and #60 of 130Journal of Innate ImmunityOAKarger Publishers · Switzerland | 1.04Q2 | 4.45 1.18 up from 2024 | 120 | 100% | $3,590 | ||
Rank 45; likely between #33 and #56 of 130Immunological ReviewsWiley · United States | 1.04Q2 | 10.51 2.00 up from 2024 | 340 | 78% | $5,000 | Rising vs field, 2022–25 | |
Rank 46; likely between #30 and #63 of 130BMC ImmunologyOABioMed Central · United Kingdom | 1.04Q2 | 3.11 0.07 up from 2024 | 198 | 100% | $3,090 | ||
Rank 47; likely between #28 and #66 of 130International ImmunologyOxford University Press · United Kingdom | 1.02Q2 | 2.77 0.01 down from 2024 | 190 | 49% | $3,530 | ||
Rank 48; likely between #28 and #76 of 130ImmunometabolismOAUnited Kingdom | 0.96Q2 | 3.97 0.60 up from 2024 | 62 | 100% | — | ||
Rank 49; likely between #29 and #78 of 130Immunotherapy AdvancesOAOxford University Press · United Kingdom | 0.96Q2 | 3.09 1.27 down from 2024 | 88 | 100% | $3,053 | ||
Rank 50; likely between #41 and #61 of 130European Journal of ImmunologyWiley · Germany | 0.96Q2 | 3.72 0.42 up from 2024 | 653 | 85% | $4,550 |
12 Immunology and Microbiology journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
Full rising list for Immunology and Microbiology
- 1Ticks and Tick-borne DiseasesOAParasitology+62% vs groupOJR 1.09 → 1.59range +38% to +91%
- 2Zoonoses and Public HealthParasitology+55% vs groupOJR 0.80 → 1.11range +26% to +90%
- 3Immunological ReviewsImmunology+52% vs groupOJR 0.76 → 1.04range +25% to +84%
- 4Parasites & VectorsOAParasitology+30% vs groupOJR 1.38 → 1.62range +20% to +41%
- 5Cellular and Molecular ImmunologyImmunology+54% vs groupOJR 2.97 → 4.09range +19% to +98%
- 6Turkish Journal of ParasitologyOAParasitology+55% vs groupOJR 0.35 → 0.48range +16% to +107%
- 7Infection and ImmunityOAParasitology+35% vs groupOJR 0.95 → 1.15range +15% to +60%
- 8BioDrugsImmunology+70% vs groupOJR 1.46 → 2.23range +15% to +151%
- 9Parasitology ResearchParasitology+28% vs groupOJR 0.77 → 0.89range +13% to +45%
- 10Pathogens and DiseaseMicrobiology+55% vs groupOJR 0.90 → 1.25range +13% to +113%
- 11European Journal of InflammationOAImmunology+75% vs groupOJR 0.20 → 0.32range +6.1% to +190%
- 12Current Opinion in ImmunologyImmunology+41% vs groupOJR 0.56 → 0.71range +0.5% to +99%
No-label zone, -9.1% to +10%Group median changeBar scale -67% to +206% (ratio scale)
6 Immunology and Microbiology journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Journal of NeuroVirologyVirology-44% vs groupOJR 1.13 → 0.57range -58% to -27%
- 2Journal of Leukocyte BiologyImmunology-29% vs groupOJR 1.37 → 0.87range -40% to -16%
- 3HLAImmunology-32% vs groupOJR 0.18 → 0.11range -49% to -9.0%
- 4Scandinavian Journal of ImmunologyImmunology-29% vs groupOJR 0.86 → 0.55range -46% to -4.8%
- 5The Journal of Experimental MedicineImmunology-15% vs groupOJR 3.23 → 2.46range -27% to -0.8%
- 6The Journal of ImmunologyImmunology-9.7% vs groupOJR 1.07 → 0.87range -18% to -0.8%
No-label zone, -9.1% to +10%Group median changeBar scale -59% to +146% (ratio scale)
Subfields of Immunology and Microbiology, compared.
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
19 additional Immunology and Microbiology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 130
- Window papers (baseline)
- 146,708 +5.3% from indicator year 2022
- Median OJR
- 0.853 +1.4% from indicator year 2022
- Rising journals (2025)
- 12Comparison-group list (12)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 77 | 81 | 84 | 87 | 84 | 88 | 92 | 96 | 96 | 99 | 100 | 109 | 113 | 118 | 117 | 124 | 126 | 135 | 135 | 131 | 134 | 128 | 131 | 132 | 133 | 130 | |
| Window papers (baseline) | 57,420 | 61,729 | 64,988 | 68,564 | 70,081 | 74,504 | 79,076 | 85,172 | 89,884 | 96,132 | 103,748 | 109,236 | 113,003 | 114,572 | 119,036 | 122,584 | 124,030 | 123,505 | 122,958 | 123,895 | 126,939 | 132,755 | 139,280 | 143,532 | 145,253 | 146,708 | |
| Median OJR | 0.70 | 0.78 | 0.80 | 0.76 | 0.79 | 0.837 | 0.88 | 0.945 | 0.98 | 1.15 | 1.11 | 1.089 | 1.07 | 1.04 | 1.052 | 1.053 | 1.092 | 0.99 | 0.954 | 0.948 | 0.89 | 0.847 | 0.841 | 0.854 | 0.87 | 0.853 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 1.9% | 116 journals |
| Retracted papers per 1,000 | Pooled rate: 1.118 per 1,000 | 102 journals |
| Output growth | Median: -14.5% | 121 journals |
| Open access share | Median: 82.5% | 130 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,340 | 99 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 25.3% | 128 journals |
| Review share | Median: 1.1% | 130 journals |
| Articles-only OJR | Median: 0.85 | 125 journals |
| Uncited share | Median: 25.6% | 130 journals |
| Citation concentration | Median: 42.4% | 130 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.